Delving into the Latest Updates on Sunvozertinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DZD 9008, DZD9008, Zegfrovy

+ [1]

Target

EGFR exon 20 x HER2 exon 20

Action

inhibitors

Mechanism

EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), HER2 exon 20 inhibitors(ERBB2 Exon 20 Mutation inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

EGFR ex20ins mutation in non-small cell lung cancerNon-small cell lung cancer stage IIIBNon-squamous non-small cell lung cancer+ [4]

Inactive Indication

HER2 Mutation Lung CancerMantle-Cell LymphomaMarginal Zone B-Cell Lymphoma+ [1]

Originator Organization

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Active Organization

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (22 Aug 2023),

EGFR ex20ins mutation in non-small cell lung cancer

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Breakthrough Therapy (China), Conditional marketing approval (China), Accelerated assessment (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC29H35ClFN7O3

InChIKeyBTMKEDDEMKKSEF-QGZVFWFLSA-N

CAS Registry2370013-12-8

This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment

Start Date01 Aug 2025

Sponsor / Collaborator

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

NCT06864624

/ RecruitingPhase 2IIT

Sunvozertinib as Neoadjuvant and Adjuvant Therapy in Stage II-IIIB Non-small-cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutation: a Single-arm, Phase 2 Study (WU-KONG20)

This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.

Start Date18 Feb 2025

Sponsor / Collaborator

Tangdu Hospital

[+1]

NCT06786208

/ Not yet recruitingNot ApplicableIIT

Real-world Study of Sunvozertinib Treatment in Locally Advanced or Metastatic EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Observe the efficacy and safety of sunvozertinib in the real world in the treatment of EGFRm aNSCLC patients with previous EGFR-TKI treatment

Start Date01 Feb 2025

Sponsor / Collaborator

Henan Cancer Hospital

100 Clinical Results associated with Sunvozertinib

Login to view more data

100 Translational Medicine associated with Sunvozertinib

Login to view more data

100 Patents (Medical) associated with Sunvozertinib

Login to view more data

36

Literatures (Medical) associated with Sunvozertinib

01 Oct 2025·CANCER LETTERS

Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial

Article

Author: Gao, Xiaoxing ; Lang, Hongli ; Zhao, Jing ; Zhong, Wei ; Chen, Minjiang ; Yip, Chingwan ; Wang, Mengzhao ; Xu, Yan ; Wang, Mei ; Liu, Xiaoyan

Currently, no chemotherapy-free therapy is approved for the first-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins). Sunvozertinib is an oral EGFR tyrosine kinase inhibitor, which has been approved in China for ≥ second-line EGFR exon20ins NSCLC. We conducted a multi-group phase 2 study of sunvozertinib, WU-KONG15 (NCT05559645), to explore its antitumor efficacy in treatment-naïve EGFR exon20ins NSCLC (Group 4). Sunvozertinib was administered at 200 mg once daily (QD). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), duration of response (DoR), overall survival (OS), and safety. Exploratory endpoints included circulating tumor DNA (ctDNA) biomarkers. As of January 15, 2025, 26 treatment-naïve patients with EGFR exon20ins NSCLC were enrolled and included in the efficacy analysis set. The median PFS was 10.1 months (95 % CI: 6.2, 13.9), with confirmed ORR of 73.1 % (95 % CI: 52.2, 88.4) and median DoR of 10.5 months (95 % CI: 7.2, 21.2). The estimated median OS was 23.1 months (95 % CI: 13.1, NE). A total of 99 patients were included in the safety analysis set. The median relative dose intensity was 98.2 %. The incidence of Grade ≥3 treatment-related adverse events was 35.4 %, including blood creatine phosphokinase increased (10.1 %), diarrhoea (8.1 %) and anaemia (8.1 %). Negativity of plasma EGFR exon20ins ctDNA correlated with better tumor response. In conclusion, sunvozertinib monotherapy demonstrated significant and durable antitumor efficacy and was well-tolerated in treatment-naïve patients with EGFR exon20ins NSCLC, suggesting its potential as a favorable first-line treatment option.

01 Jun 2025·BIOORGANIC & MEDICINAL CHEMISTRY

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

Review

Author: Patel, Harun M ; Patil, Chandragouda R ; Gawli, Chandrakant S

"Epidermal growth factor receptor (EGFR)" mutations are pivotal in the pathogenesis of "Non-Small Cell Lung Cancer (NSCLC)," which is associated with high morbidity and mortality rates. The advent of third and fourth-generation EGFR tyrosine kinase inhibitors (TKIs) has significantly advanced the therapeutic landscape for EGFR-mutant NSCLC, particularly in overcoming resistance mutations such as T790M and C797S. This review delves into the current clinical status, efficacy, safety profiles, and regulatory approvals of third-generation EGFR TKIs, including Osimertinib, Lazertinib, Furmonertinib, Aumolertinib, Rezivertinib, Befotertinib, Sunvozertinib. Furthermore, it explores emerging fourth-generation EGFR TKIs designed to address resistance mechanisms beyond those targeted by their predecessors. Notable fourth-generation candidates such as TQB3804, BPI-361175, BDTX-1535, WJ13404, QLH11811, H002, HS-10375, BBT-207, JIN-A02, and HS-10504 are highlighted for their potential to overcome the C797S mutation. The review emphasizes the importance of these advanced inhibitors in enhancing "progression-free survival and overall survival rates". By evaluating the therapeutic potential and limitations of these EGFR TKIs, this review aims to guide future research in the management of EGFR-mutant NSCLC. This acts as guiding beacon for the strategic design and development of third and fourth generation EGFR-TK inhibitors to overcome the drug resistance hurdles in the development of EGFR-TK inhibitors.

01 May 2025·Cell Reports Medicine

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

Article

Author: Yang, James Chih-Hsin ; Greillier, Laurent ; Yao, Yu ; Dong, Xiaorong ; Liang, Li ; Cheng, Ying ; Mazieres, Julien ; Nian, Weiqi ; Bazhenova, Lyudmila ; Xu, Fei ; Sun, Si ; Fan, Yun ; Ghiringhelli, François ; Han, Zhigang ; Zhao, Dahai ; Wang, Jianghong ; Wu, Lin ; Zhou, Chengzhi ; Ferreira, Bruna Pellini ; Wang, Yongsheng ; Hu, Ying ; Yu, Yan ; Huang, Jian'an ; Doucet, Ludovic ; Gao, Junzhen ; Zhou, Jianying ; Ren, Xiubao ; Zhao, Yanqiu ; Bosch-Barrera, Joaquim ; Zheng, Li ; Wang, Huijie ; Tang, Kejing ; He, Yong ; Wang, Mengzhao ; Camidge, D Ross ; Yang, Runxiang ; Sun, Meili ; Jin, Bo ; Xu, Yan ; Li, Wen ; Jänne, Pasi A ; Ding, Cuimin ; Gao, Bo ; Liu, Anwen ; John, Thomas ; Felip, Enriqueta ; Zhu, Xuehua ; Planchard, David ; Nagasaka, Misako ; Song, Xia

This is a report of biomarker analysis for sunvozertinib, a leading epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC). There is a positive correlation between positive EGFR exon20ins in plasma circulating tumor DNA (ctDNA) and advanced disease. Shorter progression-free survival and lower objective response rate (45.8% vs. 68.0%) were observed in patients with positive EGFR exon20ins compared to those with negative status. Droplet digital PCR analysis showed that the EGFR exon20ins allele in ctDNA decreased over time in 85.7% of patients, with the earliest clearance occurred after 1 week of sunvozertinib treatment. Acquired EGFR C797S is identified as a potential on-target resistance mutation to sunvozertinib. Finally, efforts are undertaken to investigate therapeutic approaches that aim to overcome the putative acquired resistance to sunvozertinib.

48

News (Medical) associated with Sunvozertinib

10 Jul 2025

·www.fiercepharma.com

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout

Regulatory approvals for Innovent Biologics and Dizal, and a positive phase 3 readout for Biokin's Bristol Myers Squibb-partnered bispecific ADC made our news this week. In the past two weeks, China approved a first-in-class weight loss drug that Innovent Biologics licensed from Eli Lilly, Dizal won an FDA approval for a challenger to Johnson & Johnson's Rybrevant, while Biokin said a China phase 3 trial of its Bristol Myers Squibb-partnered bispecific antibody-drug conjugate has met a primary endpoint. And more.1. With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugsChina has approved Innovent Biologics’ mazdutide as the world’s first dual GLP-1/glucagon receptor agonist for chronic weight management. Innovent obtained Chinese rights to the drug from Eli Lilly in 2019. In a Chinese phase 3 trial in patients who were overweight or obese, mazdutide 6mg achieved 14.8% average weight loss at 48 weeks, compared with just 0.5% for placebo.2. Dizal to challenge J&J with FDA approval for lung cancer drug ZegfrovyAstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20-mutated non-small cell lung cancer. To be marketed as Zegfrovy, the oral drug will compete with Johnson & Johnson’s infused Rybrevant, which recently moved into the first-line setting as part of a chemotherapy combination.3. Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADCA phase 3 trial of Biokin’s bispecific antibody-drug conjugate, iza-bren, has hit at least one primary endpoint. The Chinese phase 3 is testing the EGFRxHER3 ADC in pre-treated nasopharyngeal carcinoma with objective response rate and overall survival as the primary endpoints. Bristol Myers Squibb owns ex-China rights to the drug after paying $800 million upfront.4. Roche’s Chugai inks $250M Gero deal to access age-related disease targetsIn a deal potentially worth $250 million, Roche’s Chugai Pharmaceutical is tapping Gero’s AI-based platform to develop antibodies against age-related diseases. Singapore-based Gero will identify therapeutic targets, while Chugai will utilize its antibody engineering technologies. The Japanese company will hold worldwide rights to drugs born from the collaboration.5. Alphabet's Calico stitches $596M deal for Mabwell's anti-aging assetIn another pact around age-related diseases, Alphabet’s Calico Life Sciences is licensing Mabwell Bioscience’s investigational IL-11-directed therapeutics. The deal includes $25 million upfront and up to $571 million in biobucks. It covers 9MW3811, which is in phase 1 trials across China and Australia, as the Chinese biotech highlights the drug’s potential in idiopathic pulmonary fibrosis. 6. Torrent Pharma shells out $1.4B to take over controlling stake in India's JB Pharma from KKRTorrent Pharma has obtained a 46.39% stake in India’s J.B. Chemicals and Pharmaceuticals from private equity firm KKR for 119 billion rupees ($1.4 billion). Torrent can further purchase another 25% of J.B.’s shares from public shareholders. J.B.’s offerings include some hypertension and eye disease brands and CDMO services.7. Taiho’s DMD asset fails to improve functional motor test results in phase 3 trialTaiho Pharmaceutical’s Duchenne muscular dystrophy candidate pizuglanstat failed to better placebo in a phase 3 study. In ambulatory patients, the oral drug failed to show a significant difference in time to rise from the floor after one year of treatment. Another cohort, conducted in non-ambulatory patients, has also been discontinued.8. Shionogi puts more than $600M on the table for Swiss biotech's antibiotic programShionogi is paying about $6.3 million upfront and up to $604 million in milestones for a preclinical antibiotic asset from BioVersys. The candidate, coded BV500, belongs to the antibiotic class of ansamycin and is being developed for nontuberculous mycobacterial infections.Other News of Note: 9. China approves 4 new drugs, including a global first-in-class medicine10. Cell therapy biotech shares first clinical data for in vivo CAR-T that attracted $1B AstraZeneca acquisition11. Novo keeps China manufacturing investments rolling with $112M for new quality testing lab in Tianjin12. Pressuring Merck's Gardasil, China's home-made 9-valent HPV vaccine priced at 60% discount13. Southwest Airlines sues dozens of generic drugmakers for alleged price-fixing scheme14. Biotech VC raises $200M to focus on Japan’s ‘untapped source’ of innovation15. Pfizer, Astellas boost case for Xtandi in early-stage prostate cancer with combo survival win16. Fujifilm Biotechnologies takes lessons from Denmark as debut of massive NC cell culture facility looms17. Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker18. US lawmakers refresh scrutiny over GenScript's ties to China (Reuters)19. Takeda survey finds colon cancer patients feel unheard by HCPs, want more info on diagnosis, treatment20. CStone out-licenses PD-L1 inhibitor’s certain European rights to Gentili (release)

Drug ApprovalPhase 3Phase 2Clinical ResultPhase 1

10 Jul 2025

·pmlive.com

FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a subset of non-small cell lung cancer (NSCLC) patients. The drug has been authorised to treat locally advanced or metastatic NSCLC in adults with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) whose disease has progressed on or after platinum-based chemotherapy. The American Cancer Society estimates that approximately 226,650 people will be diagnosed with lung cancer in the US this year, with NSCLC accounting for around 87% of all cases. EGFR is involved in the growth and division of healthy cells. However, a mutation in the gene coding for EGFR can lead to the protein being significantly over-expressed, causing cells to grow out of control, which can lead to cancer. The FDA’s decision on Zegfrovy, which makes it the only targeted oral treatment approved in the US for EGFR exon20in NSCLC, was supported by results from the pivotal WU-KONG1 part B study. Data presented at last year’s American Society of Clinical Oncology (ASCO) annual meeting showed that Zegfrovy achieved an objective response rate of 53.3%, and a nine-month duration of response of 57%. Anti-tumour efficacy was observed regardless of amivantamab treatment, and Dizal’s drug was well tolerated with a favorable safety profile. The company’s chief executive officer, Xiaolin Zhang, said: “We are proud to have developed Zegfrovy, a first-in-class oral therapy that offers a more effective treatment option with enhanced safety and ease of administration for NSCLC patients with EGFR exon20ins.” Lead principal investigator of WU-KONG1B, Pasi Jänne, added that the approval “marks a landmark in scientific advancement and represents a meaningful milestone in addressing the long-standing unmet medical needs of this underserved patient population”. In line with the FDA’s accelerated approvals pathway, continued approval for Zegfrovy in this indication may be contingent on the verification of clinical benefit in a confirmatory trial. Alongside its authorisation of Zegfrovy, the FDA approved Thermo Fisher Scientific’s Oncomine Dx Express Test to identify patients eligible for Dial’s drug.

Drug ApprovalClinical ResultASCOAccelerated ApprovalClinical Study

07 Jul 2025

·www.fiercepharma.com

Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy

China's AstraZeneca spinout Dizal has scored its first FDA approval, gaining an accelerated nod for Zegfrovy for a rare genetic form of non-small cell lung cancer. The treatment was approved in China in 2023. Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only U.S.-endorsed oral treatment for those with a rare type of non-small cell lung cancer (NSCLC).Patients in the U.S. with EGFR exon 20 insertion mutations whose cancer has progressed after platinum-based chemotherapy are now eligible for Zegfrovy.The blessing comes 16 months after the FDA signed off on Johnson & Johnson’s infused Rybrevant in combination with chemotherapy as a first-line treatment in the indication. While Rybrevant is an EGFR-MET bispecific antibody, Zegfrovy is a first-in-class selective EGFR tyrosine kinase inhibitor (TKI).“(Zegfrovy) offers a more effective treatment option with enhanced safety and ease of administration for NSCLC patients with EGFR exon 20 insertions,” Dizal CEO Xiaolin Zhang, Ph.D., said in a release.Zhang, who served at AstraZeneca for 20 years before taking the reins at Dizal, told Fierce Pharma last year that he was in discussions with multiple drugmakers who were interested in partnering with the Shanghai-based company on Zagfrovy. Dizal already commercializes the drug in China, where it was approved in August of 2023.Since the FDA signed off on Zegfrovy last week, Dizal’s share price has increased by 10%.Dizal will try to succeed where another oral EGFR inhibitor failed in the indication. Takeda’s Exkivity, which received an accelerated FDA approval for second-line use in 2021, was withdrawn from the U.S. market two years later after it failed to beat out chemotherapy in a confirmatory trial.Supporting the FDA approval of Zagfrovy is the WU-KONG1B trial, which showed the treatment shrunk tumors in 46% of patients and provided an 11.1-month median duration of response.These figures compare to a 40% objective response rate (ORR) and an 11.1-month median duration response, which backed the accelerated nod for Rybrevant in 2021. Meanwhile, the trial supporting conditional approval of Exkivity showed a 28% ORR.Additionally, in WU-KONG1B, Zagfrovy showed an anti-tumor effect regardless of prior treatment with Rybrevant. The WU-KONG1B trial enrolled patients in Asia, Europe, North America, and South America.“Findings from WU-KONG1B have demonstrated Zegfrovy's significant therapeutic effects with consistent efficacy across both Asian and non-Asian patient populations,” Pasi Jänne, M.D., Ph.D., of Harvard Medical School and the lead principal investigator, said in the release. “Its convenient once-daily oral dosing substantially improves administration convenience and patient adherence, which is an increasingly critical factor as lung cancer care shifts toward chronic disease management.” Along with the approval, the FDA simultaneously signed off on Thermo Fisher’s Oncomine Dx Express Test as a companion diagnostic to identify patients with EGFR Exon 20 insertions.Roughly 2% of NSCLC patients have the genetic type, though it is the third most common type of EGFR mutation.Treating this type of NSCLC is “particularly challenging” because of its “unique spatial conformation, diverse mutation subtypes, and high heterogeneity,” according to Mengzhao Wang, M.D., Ph.D., the principal investigator of the WU-KONG1B study. “As a result, patients face a poor prognosis and limited treatment options.” As for the progression of Zagfrovy, much will depend on its multinational phase 3 WU-KONG28 trial. Dizal has completed enrollment in the study which will evaluate Zagfrovy versus chemotherapy in treatment-naïve patients in 16 countries.At the 2023 European Society for Medical Oncology (ESMO) conference, Dizal reported that Zegfrovy as a solo treatment in the first-line setting achieved an ORR of 79% and a median progression-free survival of 12.4 months.

Clinical ResultDrug ApprovalPhase 3Accelerated Approval

100 Deals associated with Sunvozertinib

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
EGFR ex20ins mutation in non-small cell lung cancer	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	22 Aug 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-small cell lung cancer stage IIIB	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	18 Feb 2025
Non-squamous non-small cell lung cancer	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	15 Feb 2023
HER2 mutant non-small cell lung cancer	Phase 2	United States	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
HER2 mutant non-small cell lung cancer	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
HER2 mutant non-small cell lung cancer	Phase 2	Taiwan Province	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
metastatic non-small cell lung cancer	Phase 2	United States	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
metastatic non-small cell lung cancer	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
metastatic non-small cell lung cancer	Phase 2	Taiwan Province	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	10 Jan 2023
EGFR-mutated non-small Cell Lung Cancer	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	27 Dec 2022
Marginal Zone B-Cell Lymphoma	Phase 2	China	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	01 Aug 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03974022 (WU-KONG1B, FDA \| FDA_CDER) Manual	Phase 1/2	EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion	85	Sunvozertinib 200 mg	ybpqmgxmpr(clhhlehats) = bfbylcycum dtwvgqmrtb (dwdrfftjyw, 35 - 57) View more	Positive	02 Jul 2025
NCT06182761 (WUKONG9, ESMO_ELCC2025)	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR sensitizing mutations	45	Sunvozertinib 300 mg + Anlotinib 12 mg	enermgfixd(trzcsfeobn) = agdhnabgnx juasvhdmyt (tyskhbonia ) View more	Positive	26 Mar 2025
NCT05559645 \| NCT03974022 \| CTR20192097 (WU-KONG15, Pubmed) Manual	Not Applicable	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	40	Sunvozertinib	uplqdaplty(mpvncfovge) = cksehafmhy rpctogztxc (hfcqcduqit ) View more	Positive	02 Dec 2024
NCT03974022 (WU-KONG1B, ESMO2024) Manual	Phase 2	EGFR ex20ins mutation in non-small cell lung cancer Second line EGFR Exon 20 Mutation	107	Sunvozertinib 300 mg	buhcbktwyu(eqcwkxsqbh) = sdfcyxropx dytorrzibz (rfzzqbmhzt )	Positive	14 Sep 2024
NCT03974022 (WU-KONG1B, PRNewswire) Manual	Phase 2	Non-Small Cell Lung Cancer EGFR Exon 20 Insertion	111	舒沃哲 300mg	rcdfjlgoel(qxcjapmdov) = fgiuybrtlh agfjxcdlhu (ivarwgcjsb ) View more	Positive	02 Jun 2024
WU-KONG (ASCO2024) Manual	Phase 1/2	EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion	121	Sunvozertinib	iyvstwwiif(zjvumwwmbs) = jgthjfxmqg ylhvlnzsfn (euawabitsx ) View more	Positive	24 May 2024
WU-KONG (ASCO2024) Manual	Phase 1/2		121	sunvozertinib	iyvstwwiif(zjvumwwmbs) = kginaqxamd ylhvlnzsfn (euawabitsx ) View more	Positive	24 May 2024
NCT03974022 (WU-KONG1, ASCO2024) Manual	Phase 2	EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion	184	Sunvozertinib 200 mg	qtbwpnrfpj(qmnqmrcmqn) = shuhuqycjg tvbhnifeag (fuyyabaopl ) Met View more	Positive	24 May 2024
NCT05712902 \| CTR20211009 (WU-KONG6, Pubmed 1 \| Pubmed 2 \| Lancet Respir Med) Manual	Phase 2	EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion	104	Sunvozertinib 300 mg	tlganzcvre(ksheprrpqg) = whzudpfcme lvydviaqid (ahnchhfcie, 50 - 71) View more	Positive	12 Dec 2023
NCT05559645 \| NCT03974022 (WU-KONG15, ESMO 12023 \| ESMO 22023) Manual	Phase 1/2	EGFR ex20ins mutation in non-small cell lung cancer First line EGFR Exon20 Mutation	28	Sunvozertinib 200 mg	chpplrxalj(hsnnsmmtxc) = kphhhtzove qmqxgwvgcw (craibuvtfv )	Positive	23 Oct 2023
	Phase 1/2		28	Sunvozertinib 300 mg	chpplrxalj(hsnnsmmtxc) = wglwbwnrpu qmqxgwvgcw (craibuvtfv )	Positive	23 Oct 2023
NCT05712902 \| CTR20211009 (WU-KONG6, WCLC2023) Manual	Phase 2	EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion	97	Sunvozertinib (Efficacy population)	mcjeyzdaxw(htqnnsgzzu) = rjhhtvahcn dtibbugscw (jnjykdnzwe, 50.4 - 70.6)	Positive	11 Sep 2023
NCT05712902 \| CTR20211009 (WU-KONG6, WCLC2023) Manual	Phase 2		97	Sunvozertinib (Tumor tissue EGFRexon20ins +)	mcjeyzdaxw(htqnnsgzzu) = nahrtxybnx dtibbugscw (jnjykdnzwe, 48.7 - 70.1)	Positive	11 Sep 2023